0317 0647241

WhatsApp & Call 24/7

Kisqali 200mg Tablet (Ribociclib) Price in Pakistan | Impo Medic

₨ 190,000

Description

Kisqali 200mg Tablet (Ribociclib) Price in Pakistan

Kisqali 200mg Tablet (Ribociclib) contains ribociclib, an oral targeted cancer medicine classified as a cyclin-dependent kinase 4/6 (CDK4/6) inhibitor. It is used in combination with hormonal therapy for the treatment of certain types of hormone receptor-positive (HR-positive), human epidermal growth factor receptor 2-negative (HER2-negative) breast cancer.

Kisqali is an original branded medicine developed by Novartis. Each film-coated tablet contains 200mg of ribociclib. It is prescribed as part of an oncology treatment plan for eligible patients with early-stage, advanced or metastatic breast cancer.

Uses of Kisqali 200mg

Ribociclib may be prescribed for eligible adults with:

  • Early Breast Cancer: Used with an aromatase inhibitor as adjuvant treatment for HR-positive, HER2-negative stage II and III early breast cancer at high risk of recurrence.
  • Advanced Breast Cancer: Used with an aromatase inhibitor as initial endocrine-based therapy for HR-positive, HER2-negative advanced breast cancer.
  • Metastatic Breast Cancer: Used in combination with an aromatase inhibitor or fulvestrant for eligible patients with HR-positive, HER2-negative metastatic breast cancer.
  • Hormone Receptor-Positive Breast Cancer: Helps control cancer-cell growth in patients whose breast cancer depends on hormone-related signalling pathways.

Treatment selection depends on cancer stage, hormone receptor status, HER2 status, previous treatments and the patient’s overall medical condition.

How Ribociclib Works

Ribociclib works by selectively inhibiting cyclin-dependent kinases 4 and 6 (CDK4/6). These proteins help regulate the cell cycle and allow cells to grow and divide.

In HR-positive breast cancer, CDK4/6 activity can contribute to uncontrolled cancer-cell multiplication. By blocking these proteins, ribociclib helps prevent cancer cells from progressing through the cell cycle.

Kisqali is generally combined with hormonal treatments such as letrozole, anastrozole or fulvestrant, depending on the patient’s treatment plan.

Dosage and Administration

Kisqali dosage depends on the breast cancer stage and prescribed combination therapy. The oncologist determines the appropriate dose and treatment schedule.

The standard adult regimens described in prescribing information include:

  • Early Breast Cancer: 400mg once daily, equivalent to two 200mg tablets, for 21 consecutive days followed by 7 days off treatment.
  • Advanced or Metastatic Breast Cancer: 600mg once daily, equivalent to three 200mg tablets, for 21 consecutive days followed by 7 days off treatment.

Each treatment cycle lasts 28 days. Dose reductions or interruptions may be necessary depending on treatment tolerance and laboratory results.

  • Take Kisqali orally once daily, with or without food.
  • Swallow tablets whole with water.
  • Do not crush, chew or split the tablets.
  • Follow the prescribed 21-days-on and 7-days-off schedule.
  • Take it at approximately the same time every day.
  • Do not change the dosage without consulting your oncologist.

Note: A 200mg tablet is one unit of strength, not necessarily the complete daily dose. Some patients may receive 200mg daily following dose reduction.

Precautions

  • Blood counts: Ribociclib may cause neutropenia and other reductions in blood-cell counts. Regular complete blood count monitoring is necessary.
  • Liver function: Liver enzyme elevations and liver injury may occur. Liver function tests should be performed before and during treatment.
  • Heart rhythm: Ribociclib may prolong the QT interval and increase the risk of abnormal heart rhythms. ECG monitoring is important.
  • Electrolytes: Potassium, calcium, magnesium and phosphorus levels may require monitoring.
  • Infections: Patients should report fever, chills or other signs of infection promptly.
  • Lung complications: Interstitial lung disease and pneumonitis are possible. Report new or worsening breathing difficulties.
  • Drug interactions: Strong CYP3A inhibitors, CYP3A inducers and medicines that prolong the QT interval may interact with ribociclib.
  • Pregnancy: Ribociclib may harm an unborn baby. Effective contraception and pregnancy precautions should be discussed with the treating specialist.
  • Breastfeeding: Breastfeeding should be avoided during treatment and for at least 3 weeks after the last dose according to the US prescribing information.

Regular medical supervision and laboratory monitoring are essential during treatment.

Product Information

  • Product Name: Kisqali 200mg Tablet
  • Brand Name: Kisqali
  • Generic Name: Ribociclib
  • Strength: 200mg
  • Dosage Form: Film-Coated Tablet
  • Manufacturer / Brand Owner: Novartis
  • Country of Manufacture: Depends on the specific marketed pack
  • Pack Size: Varies according to market and prescribed daily dose

FAQs Kisqali 200mg Tablet (Ribociclib) Price in Pakistan

What is Kisqali 200mg Tablet used for?

Kisqali contains ribociclib and is used with hormonal therapy for eligible patients with HR-positive, HER2-negative early, advanced or metastatic breast cancer.

What is the generic name of Kisqali?

The generic name of Kisqali is ribociclib.

How does Kisqali work?

Ribociclib blocks CDK4 and CDK6 proteins, helping slow the multiplication of certain breast cancer cells.

Is Kisqali a chemotherapy medicine?

Kisqali is a targeted cancer therapy known as a CDK4/6 inhibitor. It works differently from conventional chemotherapy.

Can Kisqali be taken with Letrozole?

Yes. Kisqali is commonly prescribed with an aromatase inhibitor such as letrozole for eligible patients with HR-positive, HER2-negative breast cancer.

How many Kisqali 200mg tablets are taken daily?

Depending on the indication, the standard adult dose may be two tablets (400mg) or three tablets (600mg) once daily. The prescribed dose must be confirmed by the oncologist.

Does Kisqali require regular blood tests?

Yes. Complete blood counts, liver function and electrolyte levels require monitoring. ECG assessments are also important because of the risk of QT prolongation.

Does Kisqali require a prescription?

Yes. Kisqali is a prescription-only oncology medicine and should be used under the supervision of a qualified oncologist.

Kisqali 200mg in Pakistan

Customers searching for Kisqali 200mg Tablet (Ribociclib) in Pakistan can contact Impo Medic for product information and order-related assistance. For queries about Kisqali 200mg price in Pakistan, original Novartis packaging or imported Ribociclib availability, product and supply details can be confirmed with the team. Prescription requirements apply.

Reviews

There are no reviews yet.

Be the first to review “Kisqali 200mg Tablet (Ribociclib) Price in Pakistan | Impo Medic”

Your email address will not be published. Required fields are marked *